Publicaciones en las que colabora con Zinnia Patricia Parra Guillén (26)

2024

  1. Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab

    Clinical Pharmacology and Therapeutics, Vol. 116, Núm. 5, pp. 1304-1313

2023

  1. A physiologically based pharmacokinetic model for V937 oncolytic virus in mice

    Frontiers in Pharmacology, Vol. 14

  2. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling

    Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632

  3. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

    PLoS Computational Biology, Vol. 19, Núm. 10

  4. Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 3, pp. 1115-1126

2022

  1. Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria

    British Journal of Pharmacology, Vol. 179, Núm. 14, pp. 3815-3830

  2. Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 1, pp. 166-177

2021

  1. A quantitative systems pharmacology model for acute viral hepatitis B

    Computational and Structural Biotechnology Journal, Vol. 19, pp. 4997-5007

  2. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration

    Frontiers in Pharmacology, Vol. 12

  3. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20

2020

  1. A quantitative systems pharmacology model for the key interleukins involved in Crohn’s disease

    Journal of Pharmacology and Experimental Therapeutics, Vol. 372, Núm. 3, pp. 299-307

  2. Disease pharmacokinetic–pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies

    British Journal of Pharmacology, Vol. 177, Núm. 14, pp. 3168-3182

  3. Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall Survival

    AAPS Journal, Vol. 22, Núm. 3

  4. Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II—Neutralizing Antibody

    Clinical Pharmacology and Therapeutics, Vol. 107, Núm. 3, pp. 597-606

2019

  1. Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model

    Molecular Genetics and Metabolism, Vol. 128, Núm. 3, pp. 367-375

  2. Immune network for viral hepatitis B: Topological representation

    European Journal of Pharmaceutical Sciences, Vol. 136

2018

  1. Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts

    Journal of Pharmacology and Experimental Therapeutics, Vol. 366, Núm. 1, pp. 96-104

  2. The long neglected player: Modeling tumor uptake to guide optimal dosing

    Clinical Cancer Research, Vol. 24, Núm. 14, pp. 3236-3238

2015

  1. Pharmacometrics Markup Language (PharmML): Opening new perspectives for model exchange in drug development

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 4, Núm. 6, pp. 316-319

  2. Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer incorporating non-linear red blood cell uptake

    Pharmaceutical Research, Vol. 32, Núm. 4, pp. 1493-1504